- Policy
- MOHW to expand ‘approval-assessment-negotiation’ project
- by Moon, sung-ho Aug 9, 2023 05:49am
- With the pilot project for the parallel operation of the ‘approval-assessment-negotiation linkage’ system that was implemented to shorten the drug reimbursement process in full swing, additional drugs are expected to be selected for the project in 2H this year. This is because the health authorities started a demand survey to select additio
- Policy
- Insurance price ceiling reeval negotiations to end on Aug 18
- by Lee, Tak-Sun Aug 9, 2023 05:49am
- The pricing negotiations for items subject to revaluations of their insurance price ceiling in Korea are taking place from the 4th to the 18th of this month. The negotiations are expected to be completed within the deadline as the National Health Insurance Service has been discussing the measures with pharmaceutical companies in advance
- Policy
- When will domestic COVID-19 Txs be officially approved?
- by Lee, Hye-Kyung Aug 8, 2023 05:30am
- Voices calling for the approval of domestic COVID-19 treatments are rising. Petitions and heated discussions are being made on the free bulletin board of the Ministry of Food and Drug Safety’s website for the marketing authorization and accelerated review of homegrown COVID-19 treatments. The items that are receiving attention on the y
- Company
- Chong Kun Dang/Cell Biotech, big match in the MicrobiomeCDMO
- by Nho, Byung Chul Aug 8, 2023 05:30am
- It is expected that CKD Bio and Cell Biotech will compete to expand the related market in the microbiome drug CDMO (Contract Development Manufacturing) field. According to the Korea Institute of Science and Technology Information, the global market for human microbiome is expected to reach 1,743.8 billion won in 2029 with a rapid average annu
- Company
- Union Korea Pharm agrees to export 8 drugs to Jurabek
- by Lee, Seok-Jun Aug 8, 2023 05:30am
- Union Korea Pharm signed an agreement to export 8 types of drugs with its Uzbekistan partner, Jurabek Laboratories. According to the company on the 7th, the 8 export items include the company’s representative antibiotics and injections such as Atrasen Tab, Serokfen Tab, Uni-Minoxidil Tab, Atorvan Tab, Kefodon Inj, and Amikacin Inj. Th
- Company
- Immuno-anticancer drugs have brought us closer
- by Jung, Sae-Im Aug 8, 2023 05:30am
- Immuno-anticancer agents are active in early lung cancer. Following 'Opdivo (Nivolumab),' which obtained the indication for adjuvant therapy before surgery for the first time, 'Keytruda (Pembrolizumab)' is also seeking to expand its scope as adjuvant therapy before and after surgery. The data shown by immuno-anticancer drugs in early lung
- Policy
- The price of 6 items of Choline alfoscerate is cut
- by Lee, Tak-Sun Aug 8, 2023 05:30am
- Despite the government's decision to limit reimbursement, the brain function-improving drug Choline Alfoscerate continues to come out with price cuts due to increased usage. It was found that 6 Choline Alfoscerate items were included in the PVA type Da negotiations this year as well. According to the industry on the 7th, negotiations were con
- Company
- ‘Competitors eye Eylea due to its many benefits’
- by Jung, Sae-Im Aug 8, 2023 05:30am
- The fact that many companies are concentrating on the development of Eylea biosimilars is proof of the many advantages owned by Eylea. We plan to continue to make known the strengths of Eylea while developing new products to continue to deliver on our patient and HCP-centric treatment strategy.” Sangok Suh, Head of the Specialty Medicine bus
- Policy
- Cough Syrup and Synatura Syrup complete PVA negotiations
- by Lee, Tak-Sun Aug 8, 2023 05:30am
- Respiratory drugs such as Cough Syrup and Synatrua Syrup were found to have been added as subjects for drug pricing negotiations under the Price-Volume Agreement (PVA) this year. The use of the items had increased significantly last year due to the sharp increase in confirmed COVID-19 cases last year. According to industry sources on
- Company
- Sales of the flu tx market increased due to the endemic
- by Chon, Seung-Hyun Aug 7, 2023 05:23am
- In the first half of the year, the outpatient prescription market for flu treatment exceeded 10 billion won in four years. As the number of flu patients surged after the end of the Corona 19 pandemic, the flu treatment market, which had disappeared over the past three years, expanded significantly. According to UBIST, a drug research institut
